This study reveals preferential sensitivity of the EGFR mutation to second-generation TKIs in NSCLC, indicating personalized treatment potential.
Key Points
The EGFR L858M/L861R mutation drives strong oncogenic signaling, leading to increased proliferation in lung cancer cells.
Inhibition assays showed that second-generation EGFR TKIs, like afatinib and poziotinib, effectively target this mutation.
First-generation and third-generation TKIs demonstrated reduced efficacy against the EGFR L858M/L861R mutation compared to second-generation therapies.
Molecular diagnosis is crucial for guiding personalized treatment strategies, especially for rare EGFR variants in NSCLC.